Labetalol Injection Shortage

• • Hospira had labetalol on shortage due to increased demand.
  • Sagent suspended production on labetalol 5 mg/mL 20 mL vials (NDC 25021-0300-20) in July 2013 and 40 mL vials in February 2014 (NDC 25021-0300-40) and the company has no estimated release date for further production.
  • West-Ward Pharmaceuticals' parent company, Hikma Pharmaceuticals, acquired several products from Bedford Laboratories in July 2014 including labetalol injection. West-Ward is not actively marketing labetalol injection.

• • Labetalol injection, Akorn, 5 mg/mL, 20 mL vial, 1 count, NDC 17478-0420-20
  • Labetalol injection, Akorn, 5 mg/mL, 40 mL vial, 1 count, NDC 17478-0420-40
  • Labetalol injection, Pfizer, 5 mg/mL, 20 mL vial, 1 count, NDC 00409-2267-20
  • Labetalol injection, Pfizer, 5 mg/mL, 4 mL Carpuject syringe, 10 count, NDC 00409-2339-34
  • Labetalol injection, Pfizer, 5 mg/mL, 40 mL vial, 1 count, NDC 00409-2267-54

Estimated Resupply Dates

• • All marketed presentations are available.